Why the study?
Does irbesartan reduce blood pressure in patients with mild-to-moderate hypertension?
Does irbesartan reduce blood pressure in patients with mild-to-moderate hypertension?
Answers are grounded in this paper and cite their sources.
Irbesartan is an effective once-daily antihypertensive agent with a tolerability profile similar to placebo.
Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively studied in the Bristol-Myers Squibb/Sanofi clinical development program. As shown in seven placebo controlled clinical trials, irbesartan provides clinically significant dose related reductions in blood pressure in patients with mild-to-moderate hypertension. Once daily dosing provides full 24 h blood pressure control with blood pressure reductions equivalent to those of twice daily dosing, and long-term control with monotherapy in a high percentage of patients. The antihypertensive effect of irbesartan is comparable to or exceeds that of leading antihypertensive agents. Whereas irbesartan demonstrates a relationship between dose and antihypertensive effect, there is no such relationship between dose and rates of adverse events or discontinuations due to adverse events, the incidence of which are comparable to those with placebo. Thus, irbesartan provides significant dose related antihypertensive effects with placebo-like tolerability.
No takes yet. Share an insight, caveat, or question.
H POULEUR (1997) conducted a review in Mild-to-moderate hypertension. Irbesartan vs. Placebo was evaluated on Blood pressure reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: